Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 11/2016

01-11-2016 | Review

NETs in cancer

Authors: Marzena Garley, Ewa Jabłońska, Dorota Dąbrowska

Published in: Tumor Biology | Issue 11/2016

Login to get access

Abstract

Many aspects of neutrophil hyperactivity and its role in numerous immune responses still remain a mystery. A new neutrophil mechanism was discovered recently, i.e., the formation of neutrophil extracellular traps (NETs). These structures, composed of DNA strands and neutrophil granule proteins, are an element of the non-specific immune response and bind pathogens to prevent their spread and ensure increased local concentrations of toxic factors. Research on this phenomenon shows that tumor-associated neutrophils (TANs) also form and release NETs. Reports on the role of NETs in the course of cancer are scarce, and the opinions on the involvement of extracellular traps in the disease are divided, indicating a dual function. There is speculation about the anti-cancer properties of NETs connected with direct killing of cancer cells or stimulation of the immune system. On the other hand, the trap structures might promote migration and immune escape of cancer cells or constitute a physical barrier between cancer cells and immune-competent cells. This article summarizes our knowledge about the proven roles of NETs in the course of cancer with particular focus on the significance of NETs as prognosis biomarkers in the course of the neoplastic process and their potential use in therapy.
Literature
1.
2.
Dunn GP, Old LJ, Schreiber RD. The immunobiology of immunosurveillance and immunoediting. Immunity. 2004;21:137–48.CrossRefPubMed
3.
Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1–50.CrossRefPubMed
4.
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.CrossRefPubMed
5.
Gasser S. Raulet. The DNA damage response arouses the immune system. Cancer Res. 2006;66:3959–62.CrossRefPubMed
6.
Dunn GP, Old LJ, Schreiber RD. The three es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–60.CrossRefPubMed
7.
MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med. 2003;348:567–8.CrossRefPubMed
8.
Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263–74.CrossRefPubMed
9.
Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive network during malignant progression. Cancer Res. 2006;66:5527–36.CrossRefPubMed
10.
11.
Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;100:203–29.
12.
Szala S. Angiogenesis and immune suppression: yin and yang of tumor progression? Postępy Hig Med Dośw. 2009;63:598–612.
13.
Sznurkowski JJ, Emerich J. Immune edition theory—immunosuppressive network in tumor microenvironment. New targets for immunotherapy. Curr. Gynecol Oncol. 2009;7:282–7.
14.
Granot Z, Jablonska J. Distinct function of neutrophil in cancer and its regulation. Mediat Inflamm. 2015;2015:701067.CrossRef
15.
Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. 2012;33:949–55.CrossRefPubMed
16.
Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006;66:4553–7.CrossRefPubMed
17.
18.
Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, Akinova T, Vachani A, Litzky L, Hancock WW, Conejo-Garcia JR, Feldman M, Albelda SM, Singhal S. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. 2014;124:5466–80.CrossRefPubMedPubMedCentral
19.
Kim J, Bae J-S. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediat Inflamm. 2016;2016:6058147.
20.
Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16:183–94.CrossRefPubMedPubMedCentral
21.
Berger-Achituv S, Brinkmann V, Abed UA, Kühn LI, Ben-Ezra J, Elhasid R, Zychlinsky AA. Proposed role for neutrophil extracellular traps in cancer immunoediting. Front Immunol. 2013.
22.
Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res. 2012;72:3153–62.CrossRefPubMedPubMedCentral
23.
Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013;218:1402–10.CrossRefPubMed
24.
Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532–5.CrossRefPubMed
25.
Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71:2411–6.CrossRefPubMed
26.
Cools-Lartigue J, Spicer J, Najmeh S, Ferri L. Neutrophil extracellular traps in cancer progression. Cell Mol Life Sci. 2014;71:4179–94.CrossRefPubMed
27.
Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y, Brinkmann V, Zychlinsky A. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176:231–41.CrossRefPubMedPubMedCentral
28.
Papayannopoulos V, Zychlinsky ANET. A new strategy for using old weapons. Trends Immunol. 2009;30:513–21.CrossRefPubMed
29.
Von Köckritz-Blickwede M, Nizet V. Innate immunity turned inside-out: antimicrobial defense by phagocyte extracellular traps. J Mol Med. 2009;87:775–83.CrossRefPubMedPubMedCentral
30.
McCormick A, Heesemann L, Wagener J, Marcos V, Hartl D, Loeffler J, Heesemann J, Ebel FNET. Formed by human neutrophils inhibit growth of the pathogenic mold aspergillus fumigatus. Microbes Infect. 2010;12:928–36.CrossRefPubMed
31.
Urban CF, Reichard U, Brinkmann V, Zychlinsky A. Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell Microbiol. 2006;8:668–76.CrossRefPubMed
32.
Guimarães-Costa AB, Nascimento MT, Froment GS, Soares RP, Morgado FN, Conceição-Silva F, Saraiva EM. Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. Proc Natl Acad Sci U S A. 2009;106:6748–53.CrossRefPubMedPubMedCentral
33.
Abi Abdallah D, Lin C, Ball C, King M, Duhamel G, Denkers E. Toxoplasma gondii triggers release of human and mouse neutrophil extracellular traps. Infect Immun. 2012;80:768–77.CrossRefPubMedPubMedCentral
34.
Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010;107:9813–8.CrossRefPubMedPubMedCentral
35.
Lögters T, Margraf S, Altrichter J, Cinatl J, Mitzner S, Windolf J, Scholz M. The clinical value of neutrophil extracellular traps. Med Microbiol Immunol. 2009;198:211–9.CrossRefPubMed
36.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.CrossRefPubMed
37.
Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med. 2006;79:123–30.PubMed
38.
Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fusch TA, Scadden DT, Wagner DD. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. PNAS. 2012;109:13076–81.CrossRefPubMedPubMedCentral
39.
Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, Bourdeau F, Kubes P, Ferri L. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123:3446–5.CrossRefPubMedCentral
40.
Metzler KD, Fuchs TA, Nauseef WM, Reumaux D, Roesler J, Schulze I, Wahn V, Papayannopoulos V, Zychlinsky A. Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. Blood. 2011;117:953–9.CrossRefPubMedPubMedCentral
41.
42.
Acuff HB, Carter KJ, Fingleton B, Gorden DL, Matrisian LM. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res. 2006;66:259–66.CrossRefPubMedPubMedCentral
43.
Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, Blacher S, Bajou K, Itoh T, Itohara S, Werb Z, Libert C, Foidart JM, Noël A. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J. 2005;19:234–6.PubMed
44.
Pahler JC, Tazzyman S, Erez N, Chen YY, Murdoch C, Nozawa H, Lewis CE, Hanahan D. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia. 2008;10:329–40.CrossRefPubMedPubMedCentral
45.
Cools-Lartigue J, Spicer J, McDonald B, Chow S, Kubes P, Ferri L. Neutrophil extracellular traps sequester circulating tumor cells in vitro and in a murine model of metastasis. Cancer Res 2012;72:Supplement 1.
46.
Sawabata N, Okumura M, Utsumi T, Inoue M, Shiono H, Minami M, Nishida T, Sawa Y. Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method. Gen Thorac Cardiovasc Surg. 2007;55:189–92.CrossRefPubMed
47.
Van Den Berg YW, Reitsma PH. Not exclusively tissue factor: neutrophil extracellular traps provide another link between chemotherapy and thrombosis. J Thromb Haemost. 2011;9:2311–2.CrossRefPubMed
48.
Tsou CC, Lo SS, Fang WL, CW W, Chen JH, Hsieh MC, Shen KH. Risk factors and management of anastomotic leakage after radical gastrectomy for gastric cancer. Hepato-Gastroenterology. 2011;58:218–23.PubMed
49.
Schussler O, Alifano M, Dermine H, Strano S, Casetta A, Sepulveda S, Chafik A, Coignard S, Rabbat A, Regnard JF. Postoperative pneumonia after major lung resection. Am J Respir Crit Care Med. 2006;173:1161–9.CrossRefPubMed
50.
Wojtukiewicz MZ, Rucińska M. Activation of blood coagulation in cancer patients: clinical implications. Nowotwory. 1999;49:381–91.
51.
Nordstrom M, Lindblad B, Anderson H. Deep venous thrombosis and occult malignancy: an epidemiology study. Br Med J. 1994;308:891–908.CrossRef
52.
Virchow R. Gesammelte. Abhaldungen zur Wissenchaftlichen Medicin. Frankfurt: FRG Meidinger Sohn 1856:477.
53.
Demers M, Wagner DD. Neutrophil extracellular traps a new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology. 2013;2:e22946–1.
54.
Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD, Extracellular DNA. Traps promote thrombosis. PNAS. 2010;107:15880–5.CrossRefPubMedPubMedCentral
55.
56.
Lazarus RA, Wagener JS. Recombinant human deoxyribonuclease I. Pharm Biotechnol 4th Edition 2013;321–36.
57.
58.
Lewis HD, Liddle J, Coote JE, Atkinson SJ, Barker MD, Bax BD, Bicker KL, Bingham RP, Campbell M, Chen YH, Chung CW, Craggs PD, Davis RP, Eberhard D, Joberty G, Lind KE, Locke K, Maller C, Martinod K, Patten C, Polyakova O, Rise CE, Rüdiger M, Sheppard RJ, Slade DJ, Thomas P, Thorpe J, Yao G, Drewes G, Wagner DD, Thompson PR, Prinjha RK, Wilson DM. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015;11:189–91.CrossRefPubMedPubMedCentral
59.
Domingo-Gonzales R, Martinez-coon GJ, Smith AJ, Smith CK, Ballinger MN, Xia M, Murray S, Kaplan MJ, Yanik GA, Moore BB. Inhibition of neutrophil extracellular trap formation after stem cell transplant by prostaglandin E2. Am J respir. Crit Care Med. 2016;193:186–97.CrossRef
60.
Vorobjeva NV, Pinegin BV. Effects of the antioxidants Trolox, Tiron and Tempol on neutrophil extracellular trap formation. Immunobiology. 2016;221:208–19.CrossRefPubMed
61.
Mohammed BM, Fisher BJ. Kraskauskas D, Farkas D, Brophy DF, fowler III AA, Natarajan R. Vitamin C: a novel regulator of neutrophil extracellular trap formation. Nutrients. 2013;5:3131–50.CrossRefPubMedPubMedCentral
Metadata
Title
NETs in cancer
Authors
Marzena Garley
Ewa Jabłońska
Dorota Dąbrowska
Publication date
01-11-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5328-z

Other articles of this Issue 11/2016

Tumor Biology 11/2016 Go to the issue

Review

Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications

Original Article

Low expression of DCXR protein indicates a poor prognosis for hepatocellular carcinoma patients

Original Article

LINC00312 inhibits the migration and invasion of bladder cancer cells by targeting miR-197-3p

Original Article

Role of miRNA dynamics and cytokine profile in governing CD44v6/Nanog/PTEN axis in oral cancer: modulating the master regulators

Original Article

HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma

Original Article

Reversion-inducing cysteine-rich protein with Kazal motifs and its regulation by glycogen synthase kinase 3 signaling in oral cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits